OSL · MEDI.OL
Medistim ASA
NOK 307.00-NOK 1.00 (-0.32%)
Medistim ASA’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
Loading market information…
OTC · BRRGF · USD
Stock price, earnings
Quote as of Feb 25, 2026, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BerGenBio ASA’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BerGenBio ASA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BerGenBio ASA is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapies for challenging conditions. This includes cancers that are immune-evasive, drug-resistant, or metastatic, as well as various respiratory diseases. Its leading drug candidate, Bemcentinib, is an orally available, small molecule AXL inhibitor that has progressed to Phase II clinical development. This involves studies across several significant cancer indications and for COVID-19. Specifically, its Phase II trials are focused on treating non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Another promising compound in its pipeline is tilvestamab, an anti-AXL antibody currently undergoing Phase Ib clinical evaluation. The company maintains a collaborative agreement with Merck & Co. concerning its clinical trial initiatives. Founded in 2007, BerGenBio ASA is headquartered in Bergen, Norway.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 307.00-NOK 1.00 (-0.32%)
Medistim ASA’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
NOK 10.54-NOK 0.10 (-0.94%)
Circio Holding ASA’s quoted price sits in the upper half of its reported 52-week range, 32.87% below the high.
NOK 25.80+NOK 0.40 (+1.57%)
Nordhealth AS’s quoted price sits in the lower half of its reported 52-week range, 32.81% below the high.
NOK 4.22+NOK 0.06 (+1.32%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 40.8% below the high.
NOK 46.70-NOK 0.80 (-1.68%)
Photocure ASA’s quoted price sits in the lower half of its reported 52-week range, 41.48% below the high.
NOK 3.02-NOK 0.04 (-1.31%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 41.92% below the high.
NOK 21.40+NOK 0.20 (+0.94%)
ArcticZymes Technologies ASA’s quoted price sits in the lower half of its reported 52-week range, 26.21% below the high.
NOK 46.00+NOK 0.10 (+0.22%)
Omda AS’s quoted price sits in the upper half of its reported 52-week range, 10.51% below the high.
